US Drug Watchdog Now Urges Persons Who Used the Type Two Diabetes Drug Invokana and Suffered Kidney Failure or a Below the Knee Amputation to Call Them About Possible Significant Compensation
WASHINGTON, Jan. 17, 2018 /PRNewswire/ — The US Drug Watchdog fears that some users of the type two diabetes drug called Invokana may have developed kidney failure or a below the knee amputation without ever knowing there could be a relationship between this diabetes drug, and these severe medical side effects. The group is now urging persons who developed these severe medical issues after using Invokana, or their family members, to call them anytime at 866-714-6466. The group wants to make certain people who may have been harmed by Invokana obtain free legal advice about potentially very significant financial compensation. http://
Possible Medical Side Effects Associated with Invokana:
- BLOOD INFECTION
- KIDNEY INJURY
- KIDNEY INFECTION
- BELOW-THE-KNEE AMPUTATIONS
- KIDNEY FAILURE
The US Drug Watchdog says, “We do not think persons who were using the stage two diabetes drug called Invokana, and then developed kidney failure or had a below the knee amputation, are aware there could be a direct relationship between this drug and these severe medical side effects – but that is exactly what we are saying. We are requesting diabetics who were using Invokana and suffered kidney failure or a below the knee amputation to call us anytime at 866-714-6466 so we can help get them to some of the nation’s leading lawyers to assist.
“Our top priority is that you be properly compensated if you have suffered serve side effects after using Invokana. Because it is so difficult to get the word out about potentially dangerous drugs for diabetics, the US Drug Watchdog is urging people with diabetes or their family members to post our press release on their Facebook Page.” http://USDrugWatchdog.
For additional information about Invokana, please visit the Consumer Safety.org website: https://www.
Invokana Case Number:(MDL) No. 2750 in New Jersey
US Drug Watchdog Now Invites a Plaintiffs Law Firm That Specialize in Defective Drugs or Medical Products to Call Them About a National Collaboration Aimed at Compensation for Innocent Victims
WASHINGTON, Jan. 9, 2018 /PRNewswire/ — According to the US Drug Watchdog, “If a law firm specializes in assisting victims of a specific defective drug or medical device on a nationwide basis and they want to expand their footprint we are urging the managing partner or a senior partner to call us at 866-714-6466 about how we might be able to help.
“Four or five years ago we were among the leading advocates in the United States for victims of an all metal hip implant failure and or the trans vaginal mesh catastrophe and if we learned one lesson in our work it would be how incredibly vital it is to get the word out about specific drug or medical device failures.
“Fast forward to today there are still potentially extremely dangerous pharmaceutical products being sold to US consumers with very little news or information about their potential side effects. There is a need for consumers to know about the side effects of defective drugs and or medical devices and we are especially focused on identifying those who have been injured.” http://
Specific Pharmaceutical the US Drug Watchdog is watching closely include:
- Victoza, Byetta, Januvia: Allegedly these drugs increase a user’s rick for pancreatic cancer but there were no warning labels related to this possibility.
- Pradaxa: Allegedly this blood thinner did not have an antidote for bleeding events until 2015.
- Xarelto—The blood thinner drug Xarelto (rivaroxaban) allegedly has been linked to serious bleeding events and deaths.
The US Drug Watchdog knows there are very passionate and skilled lawyers around the nation who stand ready to assist people who are victims of a serious side effect of a specific type of defective drug or medical device product. However, being a great attorney or law firm does not always translate into they are also capable of running a national information campaign designed to identify people who are now suffering the consequences of a specific defective drug or medical device product.
If a law firm that has an expertise in a specific defective drug or medical device and they would like to collaborate on a national awareness campaign to get the word out the US Drug Watchdog is inviting the managing or senior partner to call them anytime at 866-714-6466 to explore the possibilities. http://
US Drug Watchdog Urges Women Who Had a Laparoscopic Power Morecellation Procedure That Caused Their Uterine Cancer to Spread to Call Immediately
Oct. 2, 2014
The US Drug Watchdog is launching an initiative focused on identifying women who had a what is called a laparoscopic power morecellation treatment done, that ending up causing their uterine cancer to actually spread. For more information, potential victims are urged to contact the US Drug Watchdog anytime at 866-714-6466. http://USDrugWatchdog.Com
The US Drug Watchdog now alerting women who have uterine cancer to avoid having a procedure called a laparoscopic power morecellation without first alerting their physician to their condition. According to the FDA having this procedure done with a woman with uterine cancer could actually cause the cancer to spread. The FDA has indicated this procedure could actually “significantly worsen the patient’s likelihood of long term survival.”
The US Drug Watchdog says, “If you are a victim of uterine cancer, and you had a procedure called a laparoscopic power morecellation, and your cancer has spread, please call us immediately at 866-714-6466. We just became aware of this situation, and we fear there could be thousands of women at risk.” http://USDrugWatchdog.Com
According to a US FDA statement on April 17, 2014, “Laparoscopic power morecellation is one of several available treatments for fibroids. It is a procedure that uses a medical device to divide the uterine tissue into smaller pieces or fragments so it can be removed through a small incision in the abdomen, such as during laparoscopy.
“Uterine fibroids are non-cancerous growths that originate from the smooth muscle tissue in the wall of the uterus. According to the National Institutes of Health, most women will develop uterine fibroids at some point in their lives. While most uterine fibroids do not cause problems, they can cause symptoms, such as heavy or prolonged menstrual bleeding, pelvic pressure or pain, and frequent urination, sometimes requiring medical or surgical therapy.
“Based on an analysis of currently available data, the FDA has determined that approximately 1 in 350 women who are undergoing hysterectomy or myomectomy for fibroids have an unsuspected type of uterine cancer called uterine sarcoma. If laparoscopic power morecellation is performed in these women, there is a risk that the procedure will spread the cancerous tissue within the abdomen and pelvis, significantly worsening the patient’s likelihood of long-term survival.”
The FDA Warning Included the Following:
Based on currently available information, the FDA’s recommendations for health care professionals include:
- Be aware that the FDA discourages the use of laparoscopic power morecellation during hysterectomy or myomectomy for the treatment of women with uterine fibroids.
- Do not use laparoscopic uterine power morecellation in women with suspected or known uterine cancer.
- Carefully consider all the available treatment options for women with symptomatic uterine fibroids.
- Discuss the benefits and risks of all treatments with patients.
- After carefully weighing the risks and benefits of the procedure, if a health care professional nonetheless determines that laparoscopic power morecellation is the best therapeutic option for his or her patient, the health care professional should:
- Inform patients that their fibroid(s) may contain unexpected cancerous tissue and that laparoscopic power morecellation may spread the cancer, significantly worsening their prognosis.
- Be aware that some clinicians and medical institutions now advocate using a specimen “bag” during morecellation in an attempt to contain the uterine tissue and minimize the risk of cancer spread in the abdomen and pelvis.
For attribution please refer to the April 17, 2014 notification from the US Food and Drug Administration http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm393689.htm
The US Drug Watchdog says, “If you have had a laparoscopic power morecellation procedure done within the last three years, and you had a pre-existing condition of uterine cancer please call us at 866-714-6466, if the procedure made the cancer worse.” http://USDrugWatchdog.Com